Advertisement

Bladder Cancer Stage Development, 2004-2014 in Europe Compared With the United States: Analysis of European Population-based Cancer Registries, the United States SEER Database, and a Large Tertiary Institutional Cohort

Published:October 16, 2019DOI:https://doi.org/10.1016/j.clgc.2019.10.008

      Abstract

      Background

      The purpose of this study was to analyze trends of bladder cancer (BC) stages and incidence in Europe and the United States (US).

      Materials and Methods

      Tumor stages after radical cystectomy were assessed in a monocentric cohort from 2006 to 2016. BC incidence was assessed between 2004 and 2014 based on the German Center for Cancer Registry Data dataset at the Robert Koch Institute (n = 111,002), the Netherland Cancer Registry (n = 64,226), cancer registration statistics of England (n = 179,883), and the pooled data from the Scandinavian cancer registries, NORDCAN (n = 77,585) and the SEER (Surveillance, Epidemiology, and End Results) database (n = 184,519) for the complete populations and gender-specific subgroups. The average annual percent changes (AAPC) were used for statistical evaluation.

      Results

      Non–muscle-invasive BC (NMIBC) and muscle-invasive BC (MIBC) did not change in the institutional cohort at the point of radical cystectomy. The incidence of total BC (AAPC, −0.3), NMIBC (AAPC, −0.1), and non-metastasized MIBC (AAPC, 0.1) did not change in Germany during the time period under survey. BC total incidence in the Netherlands did not change significantly. In England and the Nordic countries, the incidence of total BC increased (AAPC, 0.8 and 0.5, respectively). In contrast, both the incidence of total BC (AAPC, −1.4), NMIBC (AAPC, −1.6), and non-metastasized MIBC (AAPC, −1.6) significantly decreased in the US.

      Conclusions

      Between 2004 and 2014 the incidence of BC was significantly sinking in the US, was stable in Germany and the Netherlands, and increased in England and the Nordic countries. Predominantly, differences in the smoking prevalence within the last decades but also gender-specific factors might be responsible for this discrepancy.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Antoni S.
        • Ferlay J.
        • Soerjomataram I.
        • Znaor A.
        • Jemal A.
        • Bray F.
        Bladder cancer incidence and mortality: a global overview and recent trends.
        Eur Urol. 2017; 71: 96-108
        • Leal J.
        • Luengo-Fernandez R.
        • Sullivan R.
        • Witjes J.A.
        Economic burden of bladder cancer across the European Union.
        Eur Urol. 2016; 69: 438-447
        • Bochner B.H.
        • Kattan M.W.
        • Vora K.C.
        • International Bladder Cancer Nomogram C
        Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer.
        J Clin Oncol. 2006; 24: 3967-3972
        • Hautmann R.E.
        • de Petriconi R.C.
        • Pfeiffer C.
        • Volkmer B.G.
        Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients.
        Eur Urol. 2012; 61: 1039-1047
        • Malmstrom P.U.
        Why has the survival of patients with bladder cancer not improved?.
        BJU Int. 2008; 101: 267-269
        • Zehnder P.
        • Studer U.E.
        • Skinner E.C.
        • et al.
        Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades.
        BJU Int. 2013; 112: E51-E58
        • Abdollah F.
        • Gandaglia G.
        • Thuret R.
        • et al.
        Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis.
        Cancer Epidemiol. 2013; 37: 219-225
        • Bryan R.T.
        • Zeegers M.P.
        • van Roekel E.H.
        • et al.
        A comparison of patient and tumour characteristics in two UK bladder cancer cohorts separated by 20 years.
        BJU Int. 2013; 112: 169-175
        • Nielsen M.E.
        • Smith A.B.
        • Meyer A.M.
        • et al.
        Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006.
        Cancer. 2014; 120: 86-95
        • Parkin D.M.
        The global burden of urinary bladder cancer.
        Scand J Urol Nephrol Suppl. 2008; : 12-20
        • Vaidya A.
        • Soloway M.S.
        • Hawke C.
        • Tiguert R.
        • Civantos F.
        De novo muscle invasive bladder cancer: is there a change in trend?.
        J Urol. 2001; 165 (discussion: 50): 47-50
        • Engholm G.
        • Ferlay J.
        • Christensen N.
        • et al.
        NORDCAN--a Nordic tool for cancer information, planning, quality control and research.
        Acta Oncol. 2010; 49: 725-736
        • Danckert B.
        • Ferlay J.
        • Engholm G.
        • et al.
        NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic countries, version 8.2 (26.03.2019). Association of the Nordic Cancer Registries. Danish Cancer Society.
        (Available at:) (Accessed: September 10, 2019)
      1. The Netherlands Cancer Registry. Dutch Cancer figures. Available at: http://www.cijfersoverkanker.nl/. Accessed: September 10, 2019.

      2. Cancer Registration Statistics, England: 2013, 2014, 2015. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/cancerregistrationstatisticscancerregistrationstatisticsengland. Accessed: September 4, 2019.

      3. National Cancer Insitute. Surveillance E, and End Results (SEER) Program Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2016 Sub (2000-2014) 2016. Available at: https://seer.cancer.gov/data-software/documentation/seerstat/nov2016/. Accessed: March 1, 2018.

        • Kim H.J.
        • Fay M.P.
        • Feuer E.J.
        • Midthune D.N.
        Permutation tests for joinpoint regression with applications to cancer rates.
        Stat Med. 2000; 19: 335-351
        • Moschini M.
        • Luzzago S.
        • Cazzaniga W.
        • et al.
        Effect of stage migration on bladder cancer: a slow but steady improvement in long-term survival rates after radical cystectomy in previous 25 years.
        Clin Genitourin Cancer. 2017; 15: e223-e228
        • Kiemeney L.A.
        • Coebergh J.W.
        • Koper N.P.
        • et al.
        Bladder cancer incidence and survival in the south-eastern part of The Netherlands, 1975-1989.
        Eur J Cancer. 1994; 30a: 1134-1137
        • Hayne D.
        • Arya M.
        • Quinn M.J.
        • Babb P.J.
        • Beacock C.J.
        • Patel H.R.
        Current trends in bladder cancer in England and Wales.
        J Urol. 2004; 172: 1051-1055
        • Malmström P.U.
        • Gårdmark T.
        • Sherif A.
        • et al.
        Incidence, survival and mortality trends of bladder cancer in Sweden 1997-2016.
        Scand J Urol. 2019; : 1-7
        • Charlton M.E.
        • Adamo M.P.
        • Sun L.
        • Deorah S.
        Bladder cancer collaborative stage variables and their data quality, usage, and clinical implications: a review of SEER data, 2004-2010.
        Cancer. 2014; 120: 3815-3825
        • David K.A.
        • Mallin K.
        • Milowsky M.I.
        • Ritchey J.
        • Carroll P.R.
        • Nanus D.M.
        Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000.
        Cancer. 2009; 115: 1435-1447
        • Nieder A.M.
        • Mackinnon J.A.
        • Huang Y.
        • Fleming L.E.
        • Koniaris L.G.
        • Lee D.J.
        Florida bladder cancer trends 1981 to 2004: minimal progress in decreasing advanced disease.
        J Urol. 2008; 179 (discussion: 495): 491-495
        • Babjuk M.
        Trends in bladder cancer incidence and mortality: success or disappointment?.
        Eur Urol. 2017; 71: 109-110
        • Power N.E.
        • Izawa J.
        Comparison of guidelines on non-muscle invasive bladder cancer (EAU, CUA, AUA, NCCN, NICE).
        Bladder Cancer. 2016; 2: 27-36
        • Cumberbatch M.G.
        • Rota M.
        • Catto J.W.
        • La Vecchia C.
        The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks.
        Eur Urol. 2016; 70: 458-466
        • Bjerregaard B.K.
        • Raaschou-Nielsen O.
        • Sorensen M.
        • et al.
        Tobacco smoke and bladder cancer--in the European Prospective Investigation into Cancer and Nutrition.
        Int J Cancer. 2006; 119: 2412-2416
        • Ng M.
        • Freeman M.K.
        • Fleming T.D.
        • et al.
        Smoking prevalence and cigarette consumption in 187 countries, 1980-2012.
        JAMA. 2014; 311: 183-192
        • Thamm M.L.T.
        Tabak - Zahlen und Fakten zum Konsum. Jahrbuch Sucht 2005. Geesthacht: Deutsche Hauptstelle für Suchtfragen e.V. (DHS), (Hrsg.).
        Neuland, 2005: 29-51
      4. Federal Statistical Office (DESTATIS SB. Absatz von Tabakwaren, Fachserie 14 Reihe 9.1.1. Available at: https://www.destatis.de/GPStatistik/receive/DESerie_serie_00000145. Accessed: September 10, 2019.

        • ( RKI) RK-I
        Gesundheit in Deutschland. Gesundheitsberichterstattung des Bundes.
        Robert Koch-Institut (RKI) (Hrsg), Berlin2006: 108
        • Warner K.E.
        • Mendez D.
        Tobacco control policy in developed countries: yesterday, today, and tomorrow.
        Nicotine Tob Res. 2010; 12: 876-887
        • Haberland J.
        • Bertz J.
        • Wolf U.
        • Ziese T.
        • Kurth B.-M.
        German Cancer Statistics 2004.
        Robert Koch-Institut, Berlin2010
        • Lewis D.R.
        • Check D.P.
        • Caporaso N.E.
        • Travis W.D.
        • Devesa S.S.
        US lung cancer trends by histologic type.
        Cancer. 2014; 120: 2883-2892
        • Van Hemelrijck M.J.
        • Michaud D.S.
        • Connolly G.N.
        • Kabir Z.
        Tobacco use and bladder cancer patterns in three western European countries.
        J Public Health (Oxf). 2009; 31: 335-344
        • Dobruch J.
        • Daneshmand S.
        • Fisch M.
        • et al.
        Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes.
        Eur Urol. 2016; 69: 300-310
        • Hemelt M.
        • Yamamoto H.
        • Cheng K.K.
        • Zeegers M.P.
        The effect of smoking on the male excess of bladder cancer: a meta-analysis and geographical analyses.
        Int J Cancer. 2009; 124: 412-419
        • Boormans J.L.
        • Zwarthoff E.C.
        Limited funds for bladder cancer research and what can we do about it.
        Bladder Cancer. 2016; 2: 49-51
        • Ploeg M.
        • Aben K.K.
        • Kiemeney L.A.
        The present and future burden of urinary bladder cancer in the world.
        World J Urol. 2009; 27: 289-293
        • Ferro M.
        • Vartolomei M.D.
        • Cantiello F.
        • et al.
        High-grade T1 on re-transurethral resection after initial high-grade T1 confers worse oncological outcomes: results of a multi-institutional study.
        Urol Int. 2018; 101: 7-15
        • Ferro M.
        • Vartolomei M.D.
        • Russo G.I.
        • et al.
        An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer.
        World J Urol. 2019; 37: 507-514
        • Vartolomei M.D.
        • Ferro M.
        • Cantiello F.
        • et al.
        Validation of neutrophil-to-lymphocyte ratio in a multi-institutional cohort of patients with T1G3 non-muscle-invasive bladder cancer.
        Clin Genitourin Cancer. 2018; 16: 445-452
        • Cantiello F.
        • Russo G.I.
        • Vartolomei M.D.
        • et al.
        Systemic inflammatory markers and oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer.
        Eur Urol Oncol. 2018; 1: 403-410
        • Duplisea J.J.
        • Mason R.J.
        • Reichard C.A.
        • et al.
        Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma.
        Can Urol Assoc J. 2019; 13: 24-28
        • Huo J.
        • Ray-Zack M.D.
        • Shan Y.
        • et al.
        Discerning patterns and quality of neoadjuvant chemotherapy use among patients with muscle-invasive bladder cancer.
        Eur Urol Oncol. 2019; 2: 497-504
        • Reardon Z.D.
        • Patel S.G.
        • Zaid H.B.
        • et al.
        Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides.
        Eur Urol. 2015; 67: 165-170
        • Hermans T.J.N.
        • Fransen van de Putte E.E.
        • Horenblas S.
        • et al.
        Perioperative treatment and radical cystectomy for bladder cancer--a population based trend analysis of 10,338 patients in the Netherlands.
        Eur J Cancer. 2016; 54: 18-26
        • Martini T.
        • Gilfrich C.
        • Mayr R.
        • et al.
        The use of neoadjuvant chemotherapy in patients with urothelial carcinoma of the bladder: current practice among clinicians.
        Clin Genitourin Cancer. 2017; 15: 356-362